What Researchers Did
Researchers conducted a randomized pilot trial to assess the safety and feasibility of hyperbaric oxygen (HBO) combined with recombinant tissue plasminogen activator (rTPA) versus rTPA alone in patients with acute myocardial infarction (AMI).
What They Found
Among 66 patients, those receiving hyperbaric oxygen (HBO) showed a 35% reduction in mean creatine phosphokinase levels at 12 and 24 hours (p = 0.03) and shorter time to pain relief and ST segment resolution. The HBO group also had no deaths compared to two in the control group, and a discharge ejection fraction of 52.4% versus 47.3% in controls, though this difference was not significant.
What This Means for Canadian Patients
This pilot study suggests that hyperbaric oxygen (HBO) combined with standard thrombolysis might be a safe and feasible adjunctive treatment for acute myocardial infarction. If confirmed in larger studies, this approach could potentially lead to faster symptom relief and reduced myocardial damage for patients experiencing a heart attack.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This was a pilot study with a small sample size (66 patients), primarily designed to assess safety and feasibility rather than definitive efficacy.